Last $12.63 USD
Change Today +0.25 / 2.02%
Volume 741.0K
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Snapshot

Open
$12.44
Previous Close
$12.38
Day High
$12.69
Day Low
$12.25
52 Week High
03/19/14 - $18.30
52 Week Low
12/30/13 - $7.37
Market Cap
1.5B
Average Volume 10 Days
1.6M
EPS TTM
$-0.81
Shares Outstanding
118.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON PHARMA PLC (HZNP)

horizon pharma plc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma plc (HZNP) Details

Horizon Pharma plc, a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). The company also provides RAYOS, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

463 Employees
Last Reported Date: 11/6/14
Founded in 2005

horizon pharma plc (HZNP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Consultant
Total Annual Compensation: $374.9K
Compensation as of Fiscal Year 2013.

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:30 PM

Horizon Pharma plc Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Paul W. Hoelscher, Chief Financial Officer and Executive Vice President of Finance, Robert F. Carey, Chief Business Officer and Executive Vice President.

Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone)

Horizon Pharma plc announced the presentation of data from five abstracts that review unmet needs in rheumatoid arthritis, that support the role of RAYOS(R) (prednisone) delayed-release tablets in reducing joint stiffness throughout the day and demonstrate the efficacy of VIMOVO(R) (naproxen/esomeprazole magnesium) in reducing pain in knee osteoarthritis. The data were presented at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting (ACR/ARHP) in Boston, MA from November 14 through November 19. Horizon partnered with Corrona, LLC, an independent organization established to help advance research and improve patient care, to study areas of unmet need in RA patient care. The analyses presented from three abstracts examined data from the CORRONA RA patient registry that has enrolled over 35,000 patients with RA. The analysis evaluated the prevalence of morning stiffness as reported by patients in the CORRONA RA registry, with data from patients followed from October 2001 to February 2014. The data demonstrated that morning stiffness continues to be reported by a high proportion of U.S. RA patients despite treatment with either non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs), and further that the overall prevalence of morning stiffness has remained relatively unchanged over the past 10 years. Patients reporting this symptom also were more likely to not be working. These findings highlight the importance of morning stiffness and the relative inability of traditional therapies to address this important symptom. The analysis was designed to evaluate the unique population of RA patients in the CORRONA registry that did not receive any RA directed therapy. The study specifically evaluated demographic and disease characteristics to determine what, if any, factors contribute to the failure of these patients to be directly treated for their RA symptoms. Notably, among those patients that had not received any directed therapy at the time of CORRONA enrollment, approximately 50 did not initiate any therapy in 12 months of registry follow-up. These data demonstrate a population of RA patients potentially receiving sub-optimal treatment. Data was presented which highlighted the positive effect of RAYOS in reducing symptoms of stiffness throughout the day. The abstract titled, 'Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA), was presented in a poster session on Monday, November 17, 2014. This analysis of data from the Circadian Administration of Prednisone in Rheumatoid Arthritis (CAPRA)-2 phase 3 clinical trial examined the recurrence of pain in the afternoon in RA patients while using RAYOS. The analysis measured reported changes in the reoccurrence of joint stiffness and pain during the day, collected by patient diaries to further characterize symptoms. Previously, a strong correlation between morning stiffness severity and morning pain was reported for the CAPRA-2 study. The analysis concluded that the addition of RAYOS to the treatment of RA patients on non-biologic DMARDs produced a statistically significant reduction in the reoccurrence of joint stiffness during the day, improvements in patient global assessment and physical function, as well as a decrease in analgesic use over the 12 week treatment period. Correlation was shown regardless of treatment between reoccurrence of joint stiffness and pain during the day, further supporting the strong patient relationships of symptoms of stiffness and pain reported previously in the CAPRA-1 study.

Horizon Pharma plc Presents at Stifel Healthcare Conference 2014, Nov-18-2014 04:45 PM

Horizon Pharma plc Presents at Stifel Healthcare Conference 2014, Nov-18-2014 04:45 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Timothy P. Walbert, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $12.63 USD +0.25

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $15.69 USD +0.145
Pfizer Inc $31.65 USD +0.23
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.